封面
市场调查报告书
商品编码
1647511

坐骨神经痛治疗市场规模、份额和成长分析(按类型、药物类别、分销管道和地区)- 产业预测 2025-2032

Sciatica Treatment Market Size, Share, and Growth Analysis, By Type (Acute, Chronic), By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids), By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2023 年全球坐骨神经痛治疗市场规模价值 7.3474 亿美元,预计将从 2024 年的 7.6486 亿美元增长到 2032 年的 10.5485 亿美元,预测期内(2025-2032 年)的复合年增长率为 4.1%。

根据市场洞察,坐骨神经痛病例呈现上升趋势,主要是由于久坐的生活方式、肥胖率上升和人口老化。此症状表现为沿着坐骨神经的放射性疼痛,并常与椎间盘突出、骨刺或脊椎狭窄有关。诊断技术的进步使得坐骨神经痛的辨识更加准确,导致报告病例数急剧增加。研究表明,大约40%的人患有坐骨神经痛,40至50岁之间的发病率最高,男性比女性更常见。随着对坐骨神经痛的认识和诊断的提高,解决坐骨神经痛的根本原因对于控制其对不断增长的患者群体的影响至关重要。

目录

介绍

  • 调查目的
  • 研究范围
  • 定义

调查方法

  • 资讯采购
  • 次要和资料资料
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态及展望

  • 市场概况
  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特的分析

主要市场考察

  • 关键成功因素
  • 竞争程度
  • 主要投资机会
  • 市场生态系统
  • 市场吸引力指数(2024 年)
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析

坐骨神经痛治疗市场规模(按类型)

  • 市场概况
  • 急性
  • 慢性的
  • 其他的

坐骨神经痛治疗市场规模(依药物类别)

  • 市场概况
  • 非类固醇消炎剂(NSAID)
  • 皮质类固醇
  • 抗忧郁症
  • 其他的

坐骨神经痛治疗市场规模(依分销管道)

  • 市场概况
  • 医院药房
  • 零售及网路药局

坐骨神经痛治疗市场规模

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲国家
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前 5 家公司对比
  • 主要企业市场定位(2024年)
  • 主要市场参与者所采用的策略
  • 近期市场趋势
  • 公司市场占有率分析(2024 年)
  • 主要企业简介
    • 公司简介
    • 产品系列分析
    • 按细分市场分析市场份额
    • 收益与前一年同期比较(2022-2024 年)

主要企业简介

  • Pfizer Inc.(United States)
  • Novartis AG(Switzerland)
  • Johnson & Johnson(United States)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Endo Pharmaceuticals(United States)
  • Stryker Corporation(United States)
  • Medtronic PLC(Ireland)
  • Abbott Laboratories(United States)
  • Bayer AG(Germany)
  • Sanofi SA(France)
  • AstraZeneca PLC(United Kingdom)
  • Amneal Pharmaceuticals, Inc.(United States)
  • Aurobindo Pharma Limited(India)
  • Sun Pharmaceutical Industries Ltd.(India)
  • Sorrento Therapeutics, Inc.(United States)
  • Alkem Laboratories Ltd.(India)
  • Eliem Therapeutics, Inc.(United States)
  • Sinfonia Biotherapeutics(United States)
  • Omega Laser Systems Ltd.(United Kingdom)

结论和建议

简介目录
Product Code: SQMIG35A2822

Global Sciatica Treatment Market size was valued at USD 734.74 million in 2023 and is poised to grow from USD 764.86 million in 2024 to USD 1054.85 million by 2032, growing at a CAGR of 4.1% during the forecast period (2025-2032).

Market insights indicate a rising trend in sciatica cases, largely influenced by sedentary lifestyles, increasing obesity rates, and an aging demographic. This condition manifests as pain radiating along the sciatic nerve, often related to herniated disks, bone spurs, or spinal stenosis. Advancements in diagnostic technologies have further improved the identification of sciatica, resulting in a surge of reported cases. Research shows that around 40% of individuals will experience sciatica at some point, with the highest frequency observed in those aged 40 to 50, and a greater prevalence in men compared to women. As awareness and diagnosis improve, addressing sciatica's underlying causes will be essential for managing its impact on the growing patient population.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sciatica Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sciatica Treatment Market Segments Analysis

Global Sciatica Treatment Market is segmented by Type, Drug Class, Distribution Channel and region. Based on Type, the market is segmented into Acute, Chronic and Others. Based on Drug Class, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Antidepressants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies and Retail & Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sciatica Treatment Market

The global Sciatica Treatment market is significantly influenced by the high prevalence of sciatica, a condition affecting 10-40% of the population, particularly among older individuals, with a lifetime occurrence rate of up to 43%. This rising incidence of both chronic and acute cases, especially in adults aged 60 and above, where rates soar to 19.2%, drives the demand for effective treatments. While surgical options like microdiscectomy or spinal fusion are available, their high costs present accessibility challenges, particularly in low- and middle-income nations with limited healthcare resources. Emerging treatments, such as stem cell therapy, though promising, may also lack adequate insurance coverage, further complicating patient access to necessary care.

Restraints in the Global Sciatica Treatment Market

The Global Sciatica Treatment market faces significant restraints primarily due to the high costs associated with surgical interventions, such as microdiscectomy and spinal fusion, which are commonly recommended for sciatica relief. Furthermore, emerging therapies like stem cell treatment, despite their potential benefits, also come with increased expenses, and there is uncertainty regarding insurance coverage for these advanced procedures. These financial burdens create substantial barriers, restricting access to various treatment options, especially for patients in low- and middle-income nations where healthcare resources are limited. Ultimately, the economic constraints significantly hinder the ability to seek adequate sciatica care for many individuals.

Market Trends of the Global Sciatica Treatment Market

The Global Sciatica Treatment Market is experiencing significant growth, driven largely by advancements in diagnostic imaging technologies such as MRI and CT scans. These innovations have transformed the identification of sciatica's underlying causes, allowing for faster and more accurate diagnoses, which facilitate timely interventions. Early detection is essential in averting the progression from acute sciatica to chronic, debilitating conditions. Enhanced diagnostic precision empowers healthcare providers to deliver effective treatments promptly, improving patient outcomes and reducing the risk of disability. Additionally, the increasing prevalence of sciatica cases is further propelling market expansion, underscoring the importance of innovative solutions in managing this condition.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Sciatica Treatment Market Size by Type & CAGR (2025-2032)

  • Market Overview
  • Acute
  • Chronic
  • Others

Global Sciatica Treatment Market Size by Drug Class & CAGR (2025-2032)

  • Market Overview
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Antidepressants
  • Others

Global Sciatica Treatment Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital Pharmacies
  • Retail & Online Pharmacies

Global Sciatica Treatment Market Size & CAGR (2025-2032)

  • North America (Type, Drug Class, Distribution Channel)
    • US
    • Canada
  • Europe (Type, Drug Class, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type, Drug Class, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type, Drug Class, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type, Drug Class, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Pfizer Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Endo Pharmaceuticals (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Stryker Corporation (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medtronic PLC (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott Laboratories (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca PLC (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amneal Pharmaceuticals, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aurobindo Pharma Limited (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sorrento Therapeutics, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alkem Laboratories Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eliem Therapeutics, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sinfonia Biotherapeutics (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Omega Laser Systems Ltd. (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations